NXTC RSI Chart
Last 7 days
1.2%
Last 30 days
10.6%
Last 90 days
14.4%
Trailing 12 Months
-6.1%
Historical Charts for Stock Metrics
Year | Q1 | Q2 | Q3 | Q4 |
---|---|---|---|---|
2020 | 27.4M | 26.0M | 24.4M | 22.4M |
2019 | 0 | 0 | 0 | 6.3M |
Datesorted ascending | Name | Buy/Sell | $ Value | Avg. Price | # Shares | Title |
---|---|---|---|---|---|---|
Jul 14, 2020 | heller kevin n. | acquired | 48,195 | 1.77 | 27,229 | chief medical officer |
Nov 27, 2019 | liu linda | acquired | 41,656 | 0.754176 | 55,234 | svp, research |
Nov 15, 2019 | sofinnova venture partners ix, l.p. | bought | 5,512,500 | 36.75 | 150,000 | - |
May 13, 2019 | orbimed advisors llc | acquired | - | - | 2,361,010 | - |
May 13, 2019 | orbimed advisors llc | bought | 5,250,000 | 15.00 | 350,000 | - |
May 13, 2019 | shannon timothy m | acquired | - | - | 2,204,440 | - |
May 13, 2019 | shannon timothy m | bought | 750,000 | 15.00 | 50,000 | - |
May 13, 2019 | khuong chau quang | acquired | - | - | 2,361,010 | - |
May 13, 2019 | khuong chau quang | bought | 5,250,000 | 15.00 | 350,000 | - |
May 13, 2019 | sofinnova venture partners ix, l.p. | acquired | - | - | 2,121,860 | - |
Which funds bought or sold NXTC recently?
View All DetailsDatesorted ascending | Fund Name | Type | % Chg | $ Change | $ Held | % Portfolio |
---|---|---|---|---|---|---|
May 15, 2024 | TWO SIGMA ADVISERS, LP | unchanged | - | 62,893 | 128,671 | -% |
May 15, 2024 | CITADEL ADVISORS LLC | reduced | -34.69 | 118,942 | 547,411 | -% |
May 15, 2024 | Royal Bank of Canada | reduced | -93.58 | - | - | -% |
May 15, 2024 | ORBIMED ADVISORS LLC | reduced | -57.91 | -545,679 | 2,544,880 | 0.05% |
May 15, 2024 | BRIDGEWAY CAPITAL MANAGEMENT, LLC | reduced | -25.37 | 49,594 | 157,438 | -% |
May 15, 2024 | HarbourVest Partners LLC | unchanged | - | 10,948 | 22,398 | 0.01% |
May 15, 2024 | TANG CAPITAL MANAGEMENT LLC | reduced | -69.11 | -211,151 | 322,280 | 0.03% |
May 15, 2024 | MILLENNIUM MANAGEMENT LLC | reduced | -0.55 | 1,228,950 | 2,528,990 | -% |
May 15, 2024 | Hudson Bay Capital Management LP | new | - | 454,474 | 454,474 | -% |
May 15, 2024 | BANK OF AMERICA CORP /DE/ | added | 10,804 | 6,050 | 6,079 | -% |
Unveiling NextCure Inc's Major ShareHolders
Date Filed | Name of Filer | Percent of Class | No. of Shares | Form Type | |
---|---|---|---|---|---|
Peers (Alternatives to NextCure Inc)
Name | Mkt Capsorted ascending | Revenue | Price %, 1M | Returns, 1Y | P/E | P/S | Rev 1-Yr | Inc 1-Yr |
---|---|---|---|---|---|---|---|---|
LARGE-CAP | ||||||||
MRNA | 50.9B | 6.8B | -8.53 | 7.44 | ||||
HILS | 22.5B | 216.3K | -2.5K | 104.0K | ||||
ALNY | 18.9B | 2.0B | -56.9 | 9.43 | ||||
BMRN | 14.7B | 2.5B | 71.65 | 5.96 | ||||
INCY | 12.8B | 3.8B | 17.2 | 3.4 | ||||
MID-CAP | ||||||||
BBIO | 5.6B | 107.9M | -10.31 | 48.09 | ||||
APLS | 5.0B | 524.1M | -12.02 | 9.57 | ||||
AXSM | 3.6B | 251.0M | -12.28 | 14.5 | ||||
ARWR | 3.1B | 240.7M | -6.53 | 12.77 | ||||
ACAD | 2.4B | 813.8M | -1.4K | 3 | ||||
SMALL-CAP | ||||||||
CPRX | 1.9B | 411.3M | 29.91 | 4.73 | ||||
NVAX | 1.8B | 996.6M | -4.58 | 1.83 | ||||
CRBP | 480.9M | 881.7K | -14.25 | 481.06 | ||||
INO | 310.9M | 4.9M | -2.49 | 63.89 | ||||
IBIO | 17.1M | 2.1M | -0.74 | 7.61 |
NextCure Inc News
Income Statement (Quarterly) | |||||||||
Description | (%) Q/Q | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Revenue | - | - | - | - | 22.00 | 2.00 | 2.00 | 1.00 | 1.00 |
Operating Expenses | -6.7% | 16.00 | 17.00 | 16.00 | 14.00 | 14.00 | 11.00 | 10.00 | 8.00 |
S&GA Expenses | -11.3% | 4.00 | 5.00 | 5.00 | 4.00 | 3.00 | 3.00 | 3.00 | 2.00 |
R&D Expenses | -5.0% | 12.00 | 13.00 | 11.00 | 11.00 | 11.00 | 9.00 | 8.00 | 7.00 |
Interest Expenses | -100.0% | - | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
Net Income | 5.5% | -15.46 | -16.37 | -14.51 | 10.00 | -10.93 | -8.43 | -8.22 | -6.15 |
Balance Sheet | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Assets | -10.1% | 115 | 128 | 140 | 153 | 168 | 184 | 190 | 206 | 223 | 242 | 258 | 275 | 291 | 307 | 316 | 333 | 343 | 356 | 205 | 213 | 145 |
Current Assets | -9.0% | 103 | 113 | 123 | 135 | 149 | 164 | 175 | 193 | 209 | 228 | 243 | 259 | 273 | 288 | 297 | 315 | 327 | 340 | 189 | 197 | 132 |
Cash Equivalents | 40.3% | 18.00 | 13.00 | 20.00 | 22.00 | 30.00 | 27.00 | 31.00 | 28.00 | 11.00 | 12.00 | 37.00 | 38.00 | 40.00 | 36.00 | 26.00 | 29.00 | 34.00 | 39.00 | 15.00 | 198 | 131 |
Net PPE | -21.4% | 7.00 | 9.00 | 10.00 | 11.00 | 11.00 | 12.00 | 12.00 | 13.00 | 13.00 | 14.00 | 14.00 | 15.00 | 15.00 | 16.00 | 16.00 | 15.00 | 13.00 | 12.00 | 12.00 | 12.00 | 12.00 |
Liabilities | 18.3% | 16.00 | 14.00 | 13.00 | 15.00 | 14.00 | 17.00 | 8.00 | 8.00 | 9.00 | 9.00 | 10.00 | 12.00 | 12.00 | 13.00 | 9.00 | 12.00 | 12.00 | 35.00 | 34.00 | 34.00 | 36.00 |
Current Liabilities | 39.2% | 10.00 | 7.00 | 7.00 | 8.00 | 6.00 | 9.00 | 6.00 | 6.00 | 6.00 | 7.00 | 7.00 | 9.00 | 8.00 | 10.00 | 6.00 | 8.00 | 8.00 | 15.00 | 13.00 | 12.00 | 10.00 |
Long Term Debt | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 |
LT Debt, Current | - | - | - | - | - | - | - | - | - | - | - | - | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 2.00 | 1.00 | 1.00 | 0.00 |
LT Debt, Non Current | - | - | - | - | - | - | - | - | - | - | - | - | 1.00 | 1.00 | 2.00 | 2.00 | 3.00 | 3.00 | 3.00 | 4.00 | 4.00 | 5.00 |
Shareholder's Equity | -13.4% | 99.00 | 114 | 126 | 138 | 154 | 168 | 182 | 198 | 214 | 233 | 248 | 264 | 279 | 294 | 307 | 322 | 332 | 321 | 171 | 179 | - |
Retained Earnings | -5.3% | -341 | -324 | -310 | -295 | -277 | -261 | -244 | -225 | -207 | -187 | -170 | -152 | -134 | -117 | -102 | -85.81 | -71.30 | -81.03 | -70.11 | -61.67 | -53.45 |
Additional Paid-In Capital | 0.4% | 441 | 439 | 437 | 435 | 433 | 431 | 428 | 426 | 424 | 421 | 418 | 416 | 413 | 411 | 408 | 406 | 404 | 403 | 241 | 240 | 1.00 |
Shares Outstanding | 0% | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | 28.00 | - | - | - | - | - | - | - | - | - |
Float | - | - | - | - | 49.00 | - | - | - | 116 | - | - | - | 209 | - | - | - | 590 | - | - | - | 236 | - |
Cashflow (Quarterly) | ||||||||||||||||||||||
Description | (%) Q/Q | 2024Q1 | 2023Q4 | 2023Q3 | 2023Q2 | 2023Q1 | 2022Q4 | 2022Q3 | 2022Q2 | 2022Q1 | 2021Q4 | 2021Q3 | 2021Q2 | 2021Q1 | 2020Q4 | 2020Q3 | 2020Q2 | 2020Q1 | 2019Q4 | 2019Q3 | 2019Q2 | 2019Q1 |
Cashflow From Operations | -18.1% | -12,606 | -10,670 | -12,778 | -14,747 | -14,779 | -8,949 | -15,001 | -14,489 | -15,447 | -13,488 | -12,662 | -17,222 | -13,911 | -6,278 | -15,673 | -12,409 | -10,594 | -9,991 | -7,947 | -10,605 | -7,080 |
Share Based Compensation | -14.7% | 1,693 | 1,984 | 2,001 | 2,125 | 2,078 | 2,326 | 2,312 | 2,242 | 2,628 | 2,510 | 2,483 | 2,787 | 2,508 | 2,344 | 2,372 | 2,187 | 1,008 | 567 | 524 | 412 | 383 |
Cashflow From Investing | 329.6% | 17,881 | 4,162 | 10,278 | 6,710 | 18,122 | 4,468 | 17,888 | 31,921 | 13,702 | -11,001 | 14,414 | 15,588 | 17,600 | 16,498 | 13,103 | 8,549 | 5,373 | -127,161 | -174,695 | -1,132 | -935 |
Cashflow From Financing | -98.6% | 1.00 | 71.00 | - | - | - | 61.00 | - | 79.00 | 60.00 | 123 | -2,630 | -404 | -354 | -398 | -363 | -414 | -240 | 161,308 | -112 | 78,877 | 2,970 |
CONDENSED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS - USD ($) $ in Thousands | 3 Months Ended | |
---|---|---|
Mar. 31, 2024 | Mar. 31, 2023 | |
Operating expenses: | ||
Research and development | $ 11,398 | $ 11,647 |
General and administrative | 4,364 | 5,424 |
Restructuring and asset impairment charges | 2,542 | |
Total operating expenses | 18,304 | 17,071 |
Loss from operations | (18,304) | (17,071) |
Other income, net | 1,197 | 975 |
Net loss | $ (17,107) | $ (16,096) |
Net loss per common share | ||
Basic (in dollars per share) | $ (0.61) | $ (0.58) |
Diluted (in dollars per share) | $ (0.61) | $ (0.58) |
Weighted average shares outstanding | ||
Basic (in shares) | 27,903,040 | 27,774,536 |
Diluted (in shares) | 27,903,040 | 27,774,536 |
Comprehensive loss: | ||
Net Income (Loss) | $ (17,107) | $ (16,096) |
Unrealized gain on marketable securities | 40 | 691 |
Total comprehensive loss | $ (17,067) | $ (15,405) |
CONDENSED BALANCE SHEETS - USD ($) $ in Thousands | Mar. 31, 2024 | Dec. 31, 2023 |
---|---|---|
Current assets: | ||
Cash and cash equivalents | $ 18,358 | $ 13,082 |
Marketable securities | 77,643 | 95,217 |
Prepaid expenses and other current assets | 6,551 | 4,426 |
Total current assets | 102,552 | 112,725 |
Property and equipment, net | 7,097 | 9,033 |
Right of use assets | 3,632 | 4,398 |
Other assets | 1,878 | 1,882 |
Total assets | 115,159 | 128,038 |
Current liabilities: | ||
Accounts payable | 4,491 | 2,330 |
Accrued liabilities and other liabilities | 5,092 | 4,553 |
Total current liabilities | 9,583 | 6,883 |
Lease liabilities, long term | 5,773 | 5,949 |
Other long-term liabilities | 755 | 785 |
Total liabilities | 16,111 | 13,617 |
Stockholders' equity: | ||
Preferred stock, par value of $0.001 per share; 10,000,000 shares authorized at March 31, 2024 and December 31, 2023; No shares issued and outstanding at March 31, 2024 and December 31, 2023 | ||
Common stock, par value of $0.001 per share; 100,000,000 shares authorized at March 31, 2024 and December 31, 2023; 27,903,627 and 27,903,027 shares issued and outstanding at March 31, 2024 and December 31, 2023, respectively | 28 | 28 |
Additional paid-in capital | 440,791 | 439,097 |
Accumulated other comprehensive loss | (182) | (222) |
Accumulated deficit | (341,589) | (324,482) |
Total stockholders' equity | 99,048 | 114,421 |
Total liabilities and stockholders' equity | $ 115,159 | $ 128,038 |